# Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression

> **NCT02178683** · PHASE3 · UNKNOWN · sponsor: **Colorado Blood Cancer Institute** · enrollment: 50 (estimated)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** Tacrolimus and MMF.

## Key facts

- **NCT ID:** NCT02178683
- **Lead sponsor:** Colorado Blood Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-11
- **Primary completion:** 2016-12
- **Final completion:** 2018-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2014-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02178683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02178683, "Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02178683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*